Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:1
članak: 1 od 2  
Back povratak na rezultate
Medicinski pregled
2017, vol. 70, br. 3-4, str. 99-106
jezik rada: engleski
vrsta rada: stručni članak
doi:10.2298/MPNS1704099M


Ispitivanje osetljivosti Acinetobacter spp na antimikrobne lekove u periodu 2012-2015. godine
University of Novi Sad, Faculty of Medicine, Department of Infectious Diseases + Clinical Center of Vojvodina, Novi Sad, Clinic of Infectious Diseases

e-adresa: sandrastefanm@yahoo.co.uk

Sažetak

Uvod. Predstavnici roda Acinetobacter važni su uzročnici bolničkih infekcija zbog velike sposobnosti preživljavanja i širenja u bolničkoj sredini kao i brzog razvoja rezistencije na brojne antibiotike. Cilj rada bio je utvrđivanje učestalosti bolničkih infekcija izazvanih Acinetobacter spp i prisustva i učestalosti rezistencije na antimikrobne lekove kod sojeva Acinetobacter spp, izolovanih iz bolesničkog materijala rutinski uzorkovanog na Klinici za infektivne bolesti Kliničkog centra Vojvodine u periodu 1.1.2012-31.12.2015. godine. Materijal i metode. Retrospektivna studija je obuhvatila 1 673 pacijenta sa dijagnozom infektivnih bolesti bakterijske etiologije lečenih na Klinici za infektivne bolesti Kliničkog centra Vojvodine. Analizom primoizolata izolovanih iz bolesničkog materijala (hemokulture, urinokulture, kulture likvora, brisa rane/dekubitusa, brisa grla i brisa kanile/tubusa i aspirat bronha) pratili smo učestalost infekcija izazvanih Acinetobacter spp i antimikrobnu rezistenciju na antibiotike. Rezultati. U toku četvorogodišnjeg ispitivanja iz hemokultura izolovano je 14/260 (5,4%) izolata Acinetobacter spp, iz urinokultura 6/198 (3,0%), iz likvora 2/43 (4,7%), iz brisa rane/dekubitusa 33/128 (25,8%), iz brisa grla 14/124 (11,3%), a iz brisa kanile/tubusa i aspiratata bronha 32/72 (44,4%) izolata. Najveću osetljivost izolati Acinetobacter spp pokazali su na kolistin (100%). Rezistencija na karbapeneme i piperacilin/tazobaktam iznosila je skoro 100% kod svih ispitanih izolata, dok je rezistencija na druge antibiotike iznosila preko 63,6%, osim na tobramicin - iznosila je 11,1%. Zaključak. Predstavnici roda Acinetobacter značajni su uzročnici bolničkih infekcija kod hospitalizovanih pacijenata. Acinetobacter spp je osetljiv jedino na kolistin (100%), a rezistentan u različitom procentu na sve ostale ispitivane antibiotike.
Za ovaj članak postoji povezani rad (ispravka, opoziv ili komentar) koji je dostupan ovde.

Ključne reči

Reference

*** (2015) Antimicrobial resistance. Geneva: World Health Organization, [updated 2016 Sep; cited 2016 Sept 19]. Available from: http://www.who.int/mediacentre/factsheets/fs194/en
Al, M.S.B., Aly, M.M., Al, humidi N.Q., Halwani, M. (2013) Incidence and prevalence of Acinetobacter baumannii in King Fahd General Hospital, Saudi Arabia. Life Sci J, 10(4): 1702-10
Aucken, H., Berlau, J., Malnick, H., Pitt, T. (1999) Distribution of Acinetobacter Species on Skin of Healthy Humans. European Journal of Clinical Microbiology & Infectious Diseases, 18(3): 179-183
Bassetti, M., Righi, E., Esposito, S., Petrosillo, N., Nicolini, L. (2008) Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future microbiology, 3(6): 649-60
Bergogne-Bérézin, E., Towner, K.J. (1996) Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev, 9(2), str. 148-65
Cisneros, J.M., Rodríguez-Baño, J. (2002) Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clinical microbiology and infection, 8(11): 687-93
Dijkshoorn, L., van Aken, E., Shunburne, L., van der Reijden, T., Bernards, A.T., Nemec, A., Towner, K.J. (2005) Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. Clinical Microbiology and Infection, 11(4): 329-332
Doi, Y., Murray, G., Peleg, A. (2015) Acinetobacter baumannii: Evolution of Antimicrobial Resistance-Treatment Options. Seminars in Respiratory and Critical Care Medicine, 36(01): 085-098
European Commission (2009) Assessment of the antibiotic resistance effects of biocides. Brussels: Scientific Committee on Emerging and Newly Identified Health Risks, [cited 2016 Sep 20]. Available from: http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf
Gerner-Smidt, P., Tjernberg, I., Ursing, J. (1991) Reliability of phenotypic tests for identification of Acinetobacter species. J Clin Microbiol, 29(2): 277-82
Goić-Barišić, I. (2012) Multiplorezistentni Acinetobacter baumannii (MRAB) - deset godina nakon pojave prvih izolata u Hrvatskoj. Infektološki glasnik, 32(2): 67-70
Hawkey, P., Bergogne-Berezin, E. (2006) Acinetobacter spp. u: Gillespie, Stephen H.; Hawkey, Peter M. [ur.] Principles and Practice of Clinical Bacteriology, Chichester, UK: Wiley-Blackwell, str. 231-244
Hsueh, P., Teng, L., Chen, C., Chen, W., Yu, C., Ho, S., Luh, K. (2002) Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerging infectious diseases, 8(8): 827-32
Jones, M.E., Draghi, D.C., Thornsberry, C., Karlowski, J.A., Sahm, D.F., Wenzel, P.R. (2014) Emerging resistance among bacterial pathogens in the intensive care unit: A European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob, 3: 14
Kallen, Alexander J., Hidron, Alicia I., Patel, J., Srinivasan, A. (2010) Multidrug Resistance among Gram‐Negative Pathogens That Caused Healthcare‐Associated Infections Reported to the National Healthcare Safety Network, 2006-2008. Infection Control and Hospital Epidemiology, 31(5): 528-531
Kim, J.W., Heo, S.T., Jin, J.S., Choi, C.H., Lee, Y.C., Jeong, Y.G., Kim, S., Lee, J.C. (2008) Characterization of Acinetobacter baumannii carrying bla(OXA-23), bla(PER-1) and armA in a Korean hospital. Clinical microbiology and infection, 14(7): 716-8
Medić, D., Mihajlović-Ukropina, M., Gusman, V., Jelesić, Z., Milosavljević, B. (2011) Rezistencija na karbapeneme kod sojeva Acinetobacter spp izolovanih iz briseva rana tokom 2009. i 2010. godine. Medicinski pregled, vol. 64, br. 11-12, str. 583-587
Peleg, A.Y., Seifert, H., Paterson, D.L. (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews, 21(3): 538-82
Popović, R., Kolak, R., Ikonić, N., Tomić, Z., Rakić, G., Šunjkić, A., Božić, T. (2012) Surveillance of antimicrobial resistance at the Clinic of anesthesia and intensive care Clinical center of Vojvodina. Medicina danas, vol. 11, br. 4-6, str. 172-180
Rosić, I., Rosić, N., Simović, S. (2013) Antimicrobial susceptibility pattern of Acinetobacter species isolated from infected wounds at a tertiary care hospital. Racionalna terapija, vol. 5, br. 2, str. 15-26
Seifert, H., Dijkshoorn, L., Gerner-Smidt, P., Pelzer, N., Tjernberg, I., Vaneechoutte, M. (1997) Distribution of Acinetobacter species on human skin: Comparison of phenotypic and genotypic identification methods. J Clin Microbiol, 35(11): 2819-25
Stoeva, T., Higgins, P.G., Bojkova, K., Seifert, H. (2008) Clonal spread of carbapenem-resistant OXA-23-positive Acinetobacter baumannii in a Bulgarian university hospital. Clinical microbiology and infection, 14(7): 723-7
Šuljagić, V., Mirović, V. (2006) Epidemiological characteristics of nosocomial bloodstream infections and their causes. Vojnosanitetski pregled, vol. 63, br. 2, str. 124-131
Tambić, A.A. (2007) Otpornost bakterija na antibiotike - vodeći problem medicine u 21. stoljeću. Medicina, 43: 7-14
Towner, K.J., Levi, K., Vlassiadi, M. (2008) Genetic diversity of carbapenem-resistant isolates of Acinetobacter baumannii in Europe. Clinical Microbiology and Infection, 14(2): 161-167
Unal, S., Garcia-Rodriguez, J.A. (2005) Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagnostic Microbiology and Infectious Disease, 53(4): 265-271
Viehman, J. A., Nguyen, M. H., Doi, Y. (2014) Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections. Drugs, 74(12): 1315-1333